Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

12.62 -0.15 (-1.21%)
Streaming Delayed Price Updated: 3:05 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials ↗
Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and... 
Via Benzinga
News headline image
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
From GH Research PLC
Via GlobeNewswire
News headline image
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
3 Psychedelic Stocks to Ride to the Moon and Beyond ↗
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
Via InvestorPlace
News headline image
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
Via InvestorPlace
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
News headline image
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 ↗
GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD ↗
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. 
Via Talk Markets
News headline image
March Recap: Largest Psychedelic Drug Stocks Up Another 5% ↗
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. 
Via Talk Markets
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
News headline image
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week ↗
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
Via Talk Markets
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.